A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops.
After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
Open the app view to save this story, compare related coverage, and continue from the same source.